How IFNAR1 signaling affects CAR T cell therapy for cancer
Prognostic and Therapeutic Implications of IFNAR1 Signaling on CAR T Cell Therapy for Cancer
This study is looking at how a special receptor can help make CAR T cell therapy work better for dogs with B cell tumors, and it’s testing a new drug to see if it can boost the treatment's effectiveness, which could also help people with similar cancers in the future.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10866516 on NIH RePORTER |
What this research studies
This research investigates the role of type I interferon receptor (IFNAR1) signaling in enhancing the effectiveness of CAR T cell therapy for treating B cell tumors. The study aims to understand how stabilizing IFNAR1 can improve T cell function and anti-tumor activity. By using canine cancer patients as a model, the research explores the potential benefits of a specific p38 inhibitor, ralimetinib, in combination with CAR T cell therapy. The findings could lead to innovative strategies for improving treatment outcomes in human patients with similar cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with refractory B cell tumors who have not responded to standard treatments.
Not a fit: Patients with non-B cell malignancies or those who have not undergone CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR T cell therapies for patients with B cell malignancies.
How similar studies have performed: Previous research has shown promising results using similar approaches in animal models, but this specific application in humans is novel.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Atherton, Matthew John — University of Pennsylvania
- Study coordinator: Atherton, Matthew John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.